Subetil	ute for f	orm 144B/	PTO			ļ.,			lete if Knov	wn	
3403(1	iute toi t	OIIII 144D				Application	Number		9/806370	1000	
				SCLOSURE		Filing Date			eptember 30.		
		STATE	MENT BY A	APPLICANT		First Named		<u>K</u>	andall K. Ho	olmes	
		(use as m	any sheets	as necessary)	Group Art U				···	
-						Examiner Na		-	2 202 00		
Sheet				of	<u>I</u>		cket Number		3,383-00		
					U.S. PAT	CENT DOCUM	IENTS				
naminer ninals*	Cite No.	Nu	S. Patent Doc mber nown)	Kind Code (If Known)		entee or Applicant d Document	Date of Publication Cited Documer MM-DD-YY	ent		ages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	•
8	1.	518210	9		Tamura		01-26-1993				
					FODETCN I	PATENT DOC	TIMENTS				
		T	Foreign	Patent Docume		ATENTOC	OWENTS			Pages, Columns, Lines,	_
taminer nitials	Cite No.	Office	1 01018	Number	Kind Code (If Known)	Name of Pa Applicant of Cit		Cit	of Publication of ed Document 1-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
M)	2.	PCT	WO 93/	3202		Domenighini		07-0	8-1993		兀
- C	3.	PCT	WO 96/0	06627		Clements		03-0	7-1996		70
1	4.	PCT	WO 97/0	02348		Pizza			3-1997		ΤC
-	5.	PCT	WO 97/0			King			3-1997		
~	6.	PCT	WO 98/4			McGhee			5-1998		1[
	7.	PCT	WO 97/2			Fontana			1-1997		45
11	8.	PCT	WO 98/			Clements			0-1998	//	#
<u> </u>	9.	PCT	WO 98/4	12375	<u> </u>	Barchfeld		10-0	1-1998		1
			OTHER	PRIOR A	RT - NON	PATENT LI	TERATURI	E DO	CUMENTS	S	
aminer	Cite No.				nagazine, journal, se	APITAL LETTERS), no erial, symposium, catalo isher, city and/or country	g, etc.) date, page(s				
R	10.	General	Meeting-	1991, Ame	rican Society f	for Microbiology	, p. 59, Abstra	ct No	. B-205.	nit, Abstracts of the	
FV.	11.									C12 Cells Induced	
1	12.					Oct. 1994, pp. 4 Cholera Toxin o				ses to Orally	10
İ		Presente	d Antige	ns, Immuno	logy, 1986, pp	o. 301 - 308, Vol.	59.				
~	13.					ubunit as a Carrie tober 1984, pp. 1				l Immune	1
1	14.	MEKAI	LANOS, I	OHN J., CI	olera Toxin C	enes: Nucleotide	Sequence, D			nd Vaccine	10
	<u>. · </u>	Develor	ment, Na	ture, Decen	nber 8, 1983, p	p. 551 - 557, Vo	1. 306.			·	1
-	15.					inst Respiratory	Viruses in Mi	ce, Ad	lvances in M	ucosal Immunology,	C
 		1995, V	ol. 3/1B,	pp. 1595 -	1598.	in and Museus		N.G.	A G 3 (al Stimulation with	╌┼╼
1	16.					mie and Mucosai y, June 1984, pp.				at Sumutation with][
17	17.									Abrogated Oral	10
. *										o. 2892 - 2897, Vol.	1
		133, No								<u> </u>	↓_
V	18.	RICHA	RDS, C.M	1., Enhance	ment of the Im	mune Response	to Non-replica	ating I	Herpes Simp	lex Virus Type-1	[
				Iucosal Adı	ninistration in	the Presence of	Cholera Toxir	ı, Vac	cine, 1997, p	p. 1065 - 1069, Vol.].
+		15, No.				DD =1	fa 61 6	-		N. Diambananiaise	+
Y~	. 19.					id 7, 1997, pp. 13				ck Diarrheagenicity	16
Ψ.	1	out Keta	ıın Aajuva	anucity, J. t	xp. ivied., Ap	ıп /, тээ/, pp. <u>т</u> .	203-1210, VO	ι. ιδο,	140. /.		<u> </u>

Examiner Signature Date Considered 3/2021

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

O I P E VOLATION

PTO/SB/08a (06-03)
Approved for use through 4/30/2003. OMB 0651-0031
atent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form :	1449A/PTO			Complete if Known	RA
				Application Number	09/806,370	C.C.
1			DISCLOSURE	Filing Date	September 30, 1999	NOW YV
STATEMENT BY APPLICANT				First Named Inventor	Holmes et al.	4 Cc. 1 8.20
				Group Art Unit	1645	ENTER COURT
(Use as many sheets as necessary)			necessary)	Examiner Name	Portner	16000
Sheet	Totalor		300			

			U.S. PATENT DOCUME	NTS			
Examiner	Cite	Document Number	Publication Date	Name of Patentee	Pages, Columns, Lines, Where		
Initials*	No.¹	Number-Kind Code ^{2(if known)}	MM-DD-YYYY or Applicant of Cited Document		MM_DD_VVV I OF APPI	or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-					
					:		
	_						

		FOREIG	N PATENT DOCUMENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
<u> </u>	AL	WO-92/19265	11-12-1992	AMGEN	· · · · · · · · · · · · · · · · · · ·	
						_

			}			•
Examiner Signature		$\overline{\mathbf{x}}$	/ ^	·		,
Diversion organicae		\prime X $/\nu$		Date	-7/	
		/) / /	Z/1/X	Dun	· 4/.	$\rightarrow \sim 1$
		4		Considered	1 1	12) 1) 9
* FXAMINER: Initial	if reference concid	aread when	Same and and alternative to the same	50.3.40[60		

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language

PTO/S8/08b (06-03)
Approved for use through 6/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

itent and Traden in ion of information unless.

Complete if Known

09/806,370

September 30, 1989

Holmes et al. Substitute for form 1449B/PTO Application Number INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor Group Art Unit (Use as many sheets as necessary) Examiner Name Sheet Attorney Docket Number

		NONPATENT LITERATURE DOCUMENTS	0
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
(El	AR	PACHUK et al., "Humoral and Cellular Immune Response to Herpes Simplex Virus-2 Glycoprotein D Generated by Facilitated DNA Immunization of Mice", in Current Topics in Microbiology and Immunology, Koprowski et al., Eds., Springer-Verlag, Berlin: Vol. 226, pages 79-89 (1998)	
- *			
			,

Examiner Signature Date Considered * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent